Excipients
Facilitating industry collaboration and data sharing on the tolerability of pharmaceutical excipient formulations
Our solution
Understand the levels of toxicity of pharmaceutical excipients to establish permissible and safe limits for these substances.
The aim of the Lhasa Excipients data sharing initiative is to facilitate the anonymous sharing of excipient and vehicle toxicity data.
As a result of this industry collaboration, Lhasa is pleased to offer a pharmaceutical excipients databse.
Being a member results in access to proprietary formulation data to help you refine your experiments, minimize animal testing and support regulatory submissions.
Contact us
Key highlights
Over 4,000 tolerability records for a total of 1,437 different pharmaceutical formulations:
Refine your experiments
Utilising proprietary data and mitigating the duplication of experiments across the landscape.
Use alternative methods for assessing chemicals
Reducing the need for and refining ongoing animal testing
Make more informed decisions
Reaching confident decisions earlier to guide safe and efficient formulations
Regulatory support
REACH
Among other aims, the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) aims to reduce animal testing by promoting the use of alternative methods of assessing chemicals.
The Lhasa Excipients data sharing initiative continues to aid industry data sharing and support REACH submissions by making propriety data easily accessible via a custom curated database.
Discover how you can become part of the Excipients data sharing consortium.
Related publications
Paper
- Jun 2026
- Carcinogenicity assessment, Data sharing, NAMs Strategy, UK Government Replacing Animals In Science Strategy
Paper
- Jun 2026
- Data sharing, In silico mutagenicity assessment, NAMs Strategy
Paper
- Apr 2026
- Data sharing, Nitrites
Recent blogs
How do you assess nitrosamine impurity risk? Work through five steps: identify where nitrosamines could form, gather existing mutagenicity and carcinogenicity data, …
by David Ponting, Senior Principal Scientist, Lhasa Limited On 24 September 2026, the US Food and Drug Administration (FDA) published a guidance …
Forced degradation study design that is both defensible and efficient requires insight into the specific reactivity of an API before work begins …